-
1
-
-
77951755278
-
Pancreatic cancer
-
Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17
-
(2010)
N Engl J Med
, vol.362
, pp. 1605-1617
-
-
Hidalgo, M.1
-
2
-
-
79951646505
-
Pharmacotherapy for pediatric soft-tissue sarcomas
-
Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmacother 2011;12:517-31
-
(2011)
Expert Opin Pharmacother
, vol.12
, pp. 517-531
-
-
Casanova, M.1
Ferrari, A.2
-
4
-
-
33745464490
-
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
-
Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6
-
(1957)
Nature
, vol.179
, pp. 663-666
-
-
Heidelberger, C.1
Chaudhuri, N.K.2
Danneberg, P.3
-
5
-
-
0014151383
-
Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells
-
Wilkoff LJ, Wilcox WS, Burdeshaw JA, et al. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst 1967;39:965-75
-
(1967)
J Natl Cancer Inst
, vol.39
, pp. 965-975
-
-
Wilkoff, L.J.1
Wilcox, W.S.2
Burdeshaw, J.A.3
-
6
-
-
78651156947
-
Experimental evaluation of potential anticancer agents. XIII. on the criteria and kinetics associated with "curability" of experimental leukemia
-
Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111
-
(1964)
Cancer Chemother Rep
, vol.35
, pp. 1-111
-
-
Skipper, H.E.1
Schabel Jr., F.M.2
Wilcox, W.S.3
-
7
-
-
0024539308
-
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
-
Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32 (Pubitemid 19098135)
-
(1989)
Journal of Clinical Oncology
, vol.7
, Issue.4
, pp. 425-432
-
-
Lokich, J.J.1
Ahlgren, J.D.2
Gullo, J.J.3
Philips, J.A.4
Fryer, J.G.5
-
8
-
-
0344109583
-
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
-
Meta-analysis Group in Cancer
-
Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8
-
(1998)
J Clin Oncol
, vol.16
, pp. 301-308
-
-
-
10
-
-
65449119562
-
Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)
-
Kinoshita T, Sasako M, Sano T, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 2009;12:37-42
-
(2009)
Gastric Cancer
, vol.12
, pp. 37-42
-
-
Kinoshita, T.1
Sasako, M.2
Sano, T.3
-
11
-
-
77949545583
-
Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma
-
Nomura T, Murakami R, Toya R, et al. Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010;76:1347-52
-
Int J Radiat Oncol Biol Phys
, vol.2010
, Issue.76
, pp. 1347-1352
-
-
Nomura, T.1
Murakami, R.2
Toya, R.3
-
12
-
-
73449122261
-
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma
-
Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009;250:950-6
-
(2009)
Ann Surg
, vol.250
, pp. 950-956
-
-
Murakami, Y.1
Uemura, K.2
Sudo, T.3
-
13
-
-
35748946650
-
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
-
DOI 10.1056/NEJMoa072252
-
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20 (Pubitemid 350044801)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.18
, pp. 1810-1820
-
-
Sakuramoto, S.1
Sasako, M.2
Yamaguchi, T.3
Kinoshita, T.4
Fujii, M.5
Nashimoto, A.6
Furukawa, H.7
Nakajima, T.8
Ohashi, Y.9
Imamura, H.10
Higashino, M.11
Yamamura, Y.12
Kurita, A.13
Arai, K.14
-
14
-
-
66149153449
-
Advancements in the management of pancreatic cancer
-
Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009;10:109-17
-
(2009)
JOP
, vol.10
, pp. 109-117
-
-
Li, J.1
Saif, M.W.2
-
16
-
-
58149155550
-
Microbial studies of 6-azauracil, an antagonist of uracil
-
Handschumacher RE, Welch AD. Microbial studies of 6-azauracil, an antagonist of uracil. Cancer Res 1956;16:965-9
-
(1956)
Cancer Res
, vol.16
, pp. 965-969
-
-
Handschumacher, R.E.1
Welch, A.D.2
-
17
-
-
0011234930
-
Studies on fluorinated pyrimidines. II. Effects on transplanted tumors
-
Heidelberger C, Griesbach L, Montag BJ, et al. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res 1958;18:305-17
-
(1958)
Cancer Res
, vol.18
, pp. 305-317
-
-
Heidelberger, C.1
Griesbach, L.2
Montag, B.J.3
-
18
-
-
0000711089
-
Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo
-
Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic- 2-C14 acid in vivo. Cancer Res 1958;18:318-28
-
(1958)
Cancer Res
, vol.18
, pp. 318-28
-
-
Chaudhuri, N.K.1
Montag, B.J.2
Heidelberger, C.3
-
19
-
-
66849099602
-
XIII international charles heidelberger symposium and 50 years of fluoropyrimidines in cancer therapy held on September 6 to 8 2007 at New York University Cancer Institute, Smilow Conference Center
-
Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992-9
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 992-999
-
-
Muggia, F.M.1
Peters, G.J.2
Landolph Jr., J.R.3
-
20
-
-
0000875305
-
Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase
-
Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 1961;236:3006-13
-
(1961)
J Biol Chem
, vol.236
, pp. 3006-3013
-
-
Hartmann, K.U.1
Heidelberger, C.2
-
21
-
-
0000741537
-
Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo
-
Danneberg PB, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. Cancer Res 1958;18:329-34
-
(1958)
Cancer Res
, vol.18
, pp. 329-334
-
-
Danneberg, P.B.1
Montag, B.J.2
Heidelberger, C.3
-
22
-
-
0020056302
-
In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas
-
Spears CP, Shahinian AH, Moran RG, et al. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-6 (Pubitemid 12173578)
-
(1982)
Cancer Research
, vol.42
, Issue.2
, pp. 450-456
-
-
Spears, C.P.1
Shahinian, A.H.2
Moran, R.G.3
-
24
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
-
Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6 (Pubitemid 17074634)
-
(1987)
Cancer Research
, vol.47
, Issue.8
, pp. 2203-2206
-
-
Heggie, G.D.1
Sommadossi, J.-P.2
Cross, D.S.3
-
25
-
-
0020353668
-
High-dose 5-fluorouracil with delayed uridine 'rescue' in mice
-
Martin DS, Stolfi RL, Sawyer RC, et al. High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 1982;42:3964-70 (Pubitemid 13198549)
-
(1982)
Cancer Research
, vol.42
, Issue.10
, pp. 3964-3970
-
-
Martin, D.S.1
Stolfi, R.L.2
Sawyer, R.C.3
-
26
-
-
50949097255
-
RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p
-
Hoskins J, Butler JS. RNA-based 5-fluorouracil toxicity requires the pseudouridylation activity of Cbf5p. Genetics 2008;179:323-30
-
(2008)
Genetics
, vol.179
, pp. 323-330
-
-
Hoskins, J.1
Butler, J.S.2
-
27
-
-
0021331040
-
5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity
-
Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil, inc. into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984;44:1358-63 (Pubitemid 14174446)
-
(1984)
Cancer Research
, vol.44
, Issue.4
, pp. 1358-1363
-
-
Schuetz, J.D.1
Wallace, H.J.2
Diasio, R.B.3
-
28
-
-
0018744377
-
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine
-
Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979;39:2406-13 (Pubitemid 9203429)
-
(1979)
Cancer Research
, vol.39
, Issue.7
, pp. 2406-2413
-
-
Houghton, J.A.1
Houghton, P.J.2
Wooten, R.S.3
-
29
-
-
0041903833
-
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
-
DOI 10.1007/s00280-003-0617-9
-
Peters GJ, Noordhuis P, Van Kuilenburg AB, et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4- dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 2003;52:1-12 (Pubitemid 36920622)
-
(2003)
Cancer Chemotherapy and Pharmacology
, vol.52
, Issue.1
, pp. 1-12
-
-
Peters, G.J.1
Noordhuis, P.2
Van Kuilenburg, A.B.P.3
Schornagel, J.H.4
Gall, H.5
Turner, S.L.6
Swart, M.S.7
Voorn, D.8
Van Gennip, A.H.9
Wanders, J.10
Holwerda, U.11
Smid, K.12
Giaccone, G.13
Fumoleau, P.14
Van Groeningen, C.J.15
-
30
-
-
0014834207
-
Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate
-
Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970;23:155-60
-
(1970)
Arch Neurol
, vol.23
, pp. 155-160
-
-
Koenig, H.1
Patel, A.2
-
32
-
-
0028609605
-
Complications and failures of subclavian-vein catheterization
-
Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994;331:1735-8
-
(1994)
N Engl J Med
, vol.331
, pp. 1735-1738
-
-
Mansfield, P.F.1
Hohn, D.C.2
Fornage, B.D.3
-
33
-
-
33645718977
-
Therapy insight: Venous-catheter-related thrombosis in cancer patients
-
Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006;3:214-22
-
(2006)
Nat Clin Pract Oncol
, vol.3
, pp. 214-222
-
-
Agnelli, G.1
Verso, M.2
-
34
-
-
0141993698
-
A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada
-
DOI 10.2165/00019053-200321140-00004
-
Maroun J, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003;21:1039-51 (Pubitemid 37255457)
-
(2003)
PharmacoEconomics
, vol.21
, Issue.14
, pp. 1039-1051
-
-
Maroun, J.A.1
Asche, C.2
Romeyer, F.3
Mukherjee, J.4
Cripps, C.5
Oza, A.6
Skillings, J.R.7
Letarte, J.8
-
35
-
-
85044700692
-
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation
-
Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7:1-93
-
(2003)
Health Technol Assess
, vol.7
, pp. 1-93
-
-
Ward, S.1
Kaltenthaler, E.2
Cowan, J.3
Brewer, N.4
-
36
-
-
0031017851
-
Patient preferences for oral versus intravenous palliative chemotherapy
-
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15 (Pubitemid 27021524)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.1
, pp. 110-115
-
-
Liu, G.1
Franssen, E.2
Fitch, M.I.3
Warner, E.4
-
37
-
-
0036159485
-
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer
-
DOI 10.1016/S0959-8049(01)00371-9, PII S0959804901003719
-
Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58 (Pubitemid 34121962)
-
(2002)
European Journal of Cancer
, vol.38
, Issue.3
, pp. 349-358
-
-
Borner, M.M.1
Schoffski, P.2
De Wit, R.3
Caponigro, F.4
Comella, G.5
Sulkes, A.6
Greim, G.7
Peters, G.J.8
Van Der Born, K.9
Wanders, J.10
De Boer, R.F.11
Martin, C.12
Fumoleau, P.13
-
38
-
-
34948892881
-
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the treatment of digestive tumors trial
-
DOI 10.1200/JCO.2006.09.8467
-
Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30 (Pubitemid 47548562)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.27
, pp. 4224-4230
-
-
Diaz-Rubio, E.1
Tabernero, J.2
Gomez-Espana, A.3
Massuti, B.4
Sastre, J.5
Chaves, M.6
Abad, A.7
Carrato, A.8
Queralt, B.9
Reina, J.J.10
Maurel, J.11
Gonzalez-Flores, E.12
Aparicio, J.13
Rivera, F.14
Losa, F.15
Aranda, E.16
-
39
-
-
53049092394
-
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study
-
Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-6
-
(2008)
Ann Oncol
, vol.19
, pp. 1720-1726
-
-
Rothenberg, M.L.1
Cox, J.V.2
Butts, C.3
-
40
-
-
73349085566
-
ML17032 trial: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
-
Ryu MH, Kang YK. ML17032 trial: capecitabine/cisplatin versus 5- fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther 2009;9:1745-51
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 1745-1751
-
-
Ryu, M.H.1
Kang, Y.K.2
-
41
-
-
63749118193
-
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial
-
Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5- fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73
-
(2009)
Ann Oncol
, vol.20
, pp. 666-673
-
-
Kang, Y.K.1
Kang, W.K.2
Shin, D.B.3
-
42
-
-
77951888102
-
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
-
Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53
-
(2010)
J Clin Oncol
, vol.28
, pp. 1547-1553
-
-
Ajani, J.A.1
Rodriguez, W.2
Bodoky, G.3
-
43
-
-
77956150646
-
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/ 3 non-inferiority study (FIRIS study)
-
Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/ 3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60
-
(2010)
Lancet Oncol
, vol.11
, pp. 853-860
-
-
Muro, K.1
Boku, N.2
Shimada, Y.3
-
44
-
-
21244497388
-
Capecitabine as adjuvant treatment for stage III colon cancer
-
DOI 10.1056/NEJMoa043116
-
Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704 (Pubitemid 41007824)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.26
, pp. 2696-2704
-
-
Twelves, C.1
Wong, A.2
Nowacki, M.P.3
Abt, M.4
Burris III, H.5
Carrato, A.6
Cassidy, J.7
Cervantes, A.8
Fagerberg, J.9
Georgoulias, V.10
Husseini, F.11
Jodrell, D.12
Koralewski, P.13
Kroning, H.14
Maroun, J.15
Marschner, N.16
McKendrick, J.17
Pawlicki, M.18
Rosso, R.19
Schuller, J.20
Seitz, J.-F.21
Stabuc, B.22
Tujakowski, J.23
Van Hazel, G.24
Zaluski, J.25
Scheithauer, W.26
more..
-
45
-
-
33646443236
-
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-06
-
DOI 10.1200/JCO.2005.04.7498
-
Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64 (Pubitemid 46622115)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.13
, pp. 2059-2064
-
-
Lembersky, B.C.1
Wieand, H.S.2
Petrelli, N.J.3
O'Connell, M.J.4
Colangelo, L.H.5
Smith, R.E.6
Seay, T.E.7
Giguere, J.K.8
Marshall, M.E.9
Jacobs, A.D.10
Colman, L.K.11
Soran, A.12
Yothers, G.13
Wolmark, N.14
-
46
-
-
0014200274
-
Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Article in Russian
-
Giller SA, Zhuk RA, Lidak MIu. Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities. Article in Russian. Dokl Akad Nauka SSSR 1967;176:332-5
-
(1967)
Dokl Akad Nauka SSSR
, vol.176
, pp. 332-335
-
-
Giller, S.A.1
Zhuk, R.A.2
Lidak, M.Iu.3
-
47
-
-
0017764250
-
Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer
-
Buroker T, Miller A, Baker L, et al. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep 1977;61:1579-80 (Pubitemid 8241631)
-
(1977)
Cancer Treatment Reports
, vol.61
, Issue.8
, pp. 1579-1580
-
-
Buroker, T.1
Miller, A.2
Baker, L.3
-
48
-
-
0029996291
-
Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations
-
Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403 (Pubitemid 26150089)
-
(1996)
Xenobiotica
, vol.26
, Issue.4
, pp. 395-403
-
-
Shimada, T.1
Yamazaki, H.2
Guengerich, F.P.3
-
49
-
-
58149383761
-
Development history and concept of an oral anticancer agent S-1 (TS-1): Its clinical usefulness and future vistas
-
Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2-15
-
(2009)
Jpn J Clin Oncol
, vol.39
, pp. 2-15
-
-
Shirasaka, T.1
-
50
-
-
0018216763
-
Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil
-
Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)- 5-fluorouracil. Gann 1978;69:763-72 (Pubitemid 9081584)
-
(1978)
Gann, The Japanese Journal of Cancer Research
, vol.69
, Issue.6
, pp. 763-772
-
-
Fujii, S.1
Ikenaka, K.2
Fukushima, M.3
Shirasaka, T.4
-
51
-
-
0018757734
-
Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
-
Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5- fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-14 (Pubitemid 9184704)
-
(1979)
Gann, The Japanese Journal of Cancer Research
, vol.70
, Issue.2
, pp. 209-214
-
-
Fujii, S.1
Kitano, S.2
Ikenaka, K.3
Shirasaka, T.4
-
52
-
-
0018576207
-
Fluorinated pyrimidine nucleosides. III. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides
-
DOI 10.1021/jm00197a010
-
Cook AF, Holman MJ, Kramer MJ, Trown PW. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5- fluoropyrimidine nucleosides. J Med Chem 1979;22:1330-5 (Pubitemid 10193598)
-
(1979)
Journal of Medicinal Chemistry
, vol.22
, Issue.11
, pp. 1330-1335
-
-
Cook, A.F.1
Holman, M.J.2
Kramer, M.J.3
Trown, P.W.4
-
53
-
-
0018821981
-
Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine
-
Ishitsuka H, Miwa M, Takemoto K, et al. Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5- fluorouridine. Gann 1980;71:112-23 (Pubitemid 10100453)
-
(1980)
Gann, The Japanese Journal of Cancer Research
, vol.71
, Issue.1
, pp. 112-123
-
-
Ishitsuka, H.1
Miwa, M.2
Takemoto, K.3
-
54
-
-
0032401829
-
Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors
-
Liu M, Cao D, Russell R, et al. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 1998;58:5418-24 (Pubitemid 28551125)
-
(1998)
Cancer Research
, vol.58
, Issue.23
, pp. 5418-5424
-
-
Liu, M.1
Cao, D.2
Russell, R.3
Handschumacher, R.E.4
Pizzorno, G.5
-
55
-
-
33846189387
-
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines
-
DOI 10.1016/j.biocel.2006.10.009, PII S1357272506003013
-
Temmink OH, de Bruin M, Turksma AW, et al. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007;39:565-75 (Pubitemid 46096794)
-
(2007)
International Journal of Biochemistry and Cell Biology
, vol.39
, Issue.3
, pp. 565-575
-
-
Temmink, O.H.1
De Bruin, M.2
Turksma, A.W.3
Cricca, S.4
Laan, A.C.5
Peters, G.J.6
-
56
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
-
DOI 10.1016/S0959-8049(98)00058-6, PII S0959804998000586
-
Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81 (Pubitemid 28342121)
-
(1998)
European Journal of Cancer
, vol.34
, Issue.8
, pp. 1274-1281
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
Sawada, N.4
Ishikawa, T.5
Mori, K.6
Shimma, N.7
Umeda, I.8
Ishitsuka, H.9
-
57
-
-
0033945216
-
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine
-
DOI 10.1016/S0968-0896(00)00087-0, PII S0968089600000870
-
Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg. Med Chem 2000;8:1697-706 (Pubitemid 30427234)
-
(2000)
Bioorganic and Medicinal Chemistry
, vol.8
, Issue.7
, pp. 1697-1706
-
-
Shimma, N.1
Umeda, I.2
Arasaki, M.3
Murasaki, C.4
Masubuchi, K.5
Kohchi, Y.6
Miwa, M.7
Ura, M.8
Sawada, N.9
Tahara, H.10
Kuruma, I.11
Horii, I.12
Ishitsuka, H.13
-
58
-
-
79952321958
-
Capecitabine and hand-foot syndrome
-
Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011;10:159-69
-
Expert Opin Drug Saf
, vol.2011
, Issue.10
, pp. 159-169
-
-
Saif, M.W.1
-
59
-
-
0141563717
-
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer
-
DOI 10.1007/s00280-003-0642-8
-
Reigner B, Watanabe T, Schuller J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52:193-201 (Pubitemid 37204532)
-
(2003)
Cancer Chemotherapy and Pharmacology
, vol.52
, Issue.3
, pp. 193-201
-
-
Reigner, B.1
Watanabe, T.2
Schuller, J.3
Lucraft, H.4
Sasaki, Y.5
Bridgewater, J.6
Saeki, T.7
McAleer, J.8
Kuranami, M.9
Poole, C.10
Kimura, M.11
Monkhouse, J.12
Yorulmaz, C.13
Weidekamm, E.14
Grange, S.15
-
60
-
-
0037430550
-
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine
-
DOI 10.1016/S0960-894X(02)01082-X
-
Hattori K, Kohchi Y, Oikawa N, et al. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg Med Chem Lett 2003;13:867-72 (Pubitemid 36255556)
-
(2003)
Bioorganic and Medicinal Chemistry Letters
, vol.13
, Issue.5
, pp. 867-872
-
-
Hattori, K.1
Kohchi, Y.2
Oikawa, N.3
Suda, H.4
Ura, M.5
Ishikawa, T.6
Miwa, M.7
Endoh, M.8
Eda, H.9
Tanimura, H.10
Kawashima, A.11
Horii, I.12
Ishitsuka, H.13
Shimma, N.14
-
61
-
-
0029835349
-
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
-
Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57 (Pubitemid 26276346)
-
(1996)
Anti-Cancer Drugs
, vol.7
, Issue.5
, pp. 548-557
-
-
Shirasaka, T.1
Shimamato, Y.2
Ohshimo, H.3
Yamaguchi, M.4
Kato, T.5
Yonekura, K.6
Fukushima, M.7
-
62
-
-
0023250474
-
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts
-
Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-55 (Pubitemid 17132408)
-
(1987)
Japanese Journal of Cancer Research
, vol.78
, Issue.7
, pp. 748-755
-
-
Tatsumi, K.1
Fukushima, M.2
Shirasaka, T.3
Fujii, S.4
-
63
-
-
0027227591
-
Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
-
Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9 (Pubitemid 23267702)
-
(1993)
Cancer Research
, vol.53
, Issue.17
, pp. 4004-4009
-
-
Shirasaka, T.1
Shimamoto, Y.2
Fukushima, M.3
-
64
-
-
0000455889
-
Investigations with 5-azaorotic acid an inhibitor of the biosynthesis of pyrimidines de novo
-
Granat P, Creasey WA, Calabresi P, Handschumacher RE. Investigations with 5-azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin Pharmacol Ther 1965;6:436-47
-
(1965)
Clin Pharmacol Ther
, vol.6
, pp. 436-447
-
-
Granat, P.1
Creasey, W.A.2
Calabresi, P.3
Handschumacher, R.E.4
-
66
-
-
6544263262
-
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug
-
Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-5 (Pubitemid 29399250)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.8
, pp. 2000-2005
-
-
Hirata, K.1
Horikoshi, N.2
Aiba, K.3
Okazaki, M.4
Denno, R.5
Sasaki, K.6
Nakano, Y.7
Ishizuka, H.8
Yamada, Y.9
Uno, S.10
Taguchi, T.11
Shirasaka, T.12
-
67
-
-
40749087276
-
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
-
DOI 10.1158/1078-0432.CCR-07-1225
-
Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13 (Pubitemid 351377972)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 8-13
-
-
Yen-Revollo, J.L.1
Goldberg, R.M.2
McLeod, H.L.3
-
68
-
-
33646469073
-
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
-
Yamashita T, Ueda Y, Fuji N, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol 2006;58:183-8
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, pp. 183-188
-
-
Yamashita, T.1
Ueda, Y.2
Fuji, N.3
-
69
-
-
33645981893
-
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): Toxicity reduction and increased antitumor activity in mice
-
Saif MW, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol 2006;58:136-42
-
(2006)
Cancer Chemother Pharmacol
, vol.58
, pp. 136-142
-
-
Saif, M.W.1
Von Borstel, R.2
-
70
-
-
40749153540
-
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
-
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21
-
(2008)
Lancet Oncol
, vol.9
, pp. 215-221
-
-
Koizumi, W.1
Narahara, H.2
Hara, T.3
-
71
-
-
71249128928
-
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
-
Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9
-
(2009)
Lancet Oncol
, vol.10
, pp. 1063-1069
-
-
Boku, N.1
Yamamoto, S.2
Fukuda, H.3
-
72
-
-
79953025190
-
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
-
Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011;14:72-80
-
Gastric Cancer
, vol.2011
, Issue.14
, pp. 72-80
-
-
Narahara, H.1
Iishi, H.2
Imamura, H.3
-
73
-
-
77954922535
-
First-line treatment of patients with metastatic pancreatic cancer: Results of a Phase II trial with S-1 (CESAR-Study group)
-
Strumberg D, Bergmann L, Graeven U, et al. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group). Int J Clin Pharmacol Ther 2010;48:470-2
-
Int J Clin Pharmacol Ther
, vol.2010
, Issue.48
, pp. 470-472
-
-
Strumberg, D.1
Bergmann, L.2
Graeven, U.3
-
74
-
-
4143123301
-
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies
-
DOI 10.1158/1078-0432.CCR-04-0469
-
Chu QS, Hammond LA, Schwartz G, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004;10:4913-21 (Pubitemid 39099764)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.15
, pp. 4913-4921
-
-
Chu, Q.S.-C.1
Hammond, L.A.2
Schwartz, G.3
Ochoa, L.4
Rha, S.-Y.5
Denis, L.6
Molpus, K.7
Roedig, B.8
Letrent, S.P.9
Damle, B.10
DeCillis, A.P.11
Rowinsky, E.K.12
-
75
-
-
0037243332
-
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors
-
Hoff PM, Saad ED, Ajani JA, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-42 (Pubitemid 36109725)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.1
, pp. 134-142
-
-
Hoff, P.M.1
Saad, E.D.2
Ajani, J.A.3
Lassere, Y.4
Wenske, C.5
Medgyesy, D.6
Dwivedy, S.7
Russo, M.8
Pazdur, R.9
-
76
-
-
18244414936
-
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
-
van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-9 (Pubitemid 30463561)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.14
, pp. 2772-2779
-
-
Van Groeningen, C.J.1
Peters, G.J.2
Schornagel, J.H.3
Gall, H.4
Noordhuis, P.5
De Vries, M.J.6
Turner, S.L.7
Swart, M.S.8
Pinedo, H.M.9
Hanauske, A.R.10
Giaccone, G.11
-
77
-
-
79952082092
-
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
-
Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011;102:478-83
-
(2011)
Cancer Sci
, vol.102
, pp. 478-483
-
-
Chuah, B.1
Goh, B.C.2
Lee, S.C.3
-
78
-
-
3042668095
-
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
-
DOI 10.1158/1078-0432.CCR-1076-03
-
Peters GJ, Noordhuis P, Van Groeningen CJ, et al. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004;10:4072-6 (Pubitemid 38812484)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.12
, pp. 4072-4076
-
-
Peters, G.J.1
Noordhuis, P.2
Van Groeningen, C.J.3
Giaccone, G.4
Holwerda, U.5
Voorn, D.6
Schrijvers, A.7
Schornagel, J.H.8
Beijnen, J.H.9
Fumoleau, P.10
Schellens, J.H.M.11
-
79
-
-
84859756288
-
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
-
Epub ahead of print
-
Scheulen ME, Saito K, Hilger RA, et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; [Epub ahead of print]
-
(2011)
Cancer Chemother Pharmacol
-
-
Scheulen, M.E.1
Saito, K.2
Hilger, R.A.3
-
80
-
-
0000508052
-
Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum
-
Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 1963;45:721-9
-
(1963)
Gastroenterology
, vol.45
, pp. 721-729
-
-
Lipkin, M.1
Sherlock, P.2
Bell, B.3
-
81
-
-
0000850597
-
Kinetics of proliferation of cancer cells in neoplastic effusions in man
-
Clarkson B, Ota K, Ohkita T, et al. Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 1965;18:1189-213
-
(1965)
Cancer
, vol.18
, pp. 1189-213
-
-
Clarkson, B.1
Ota, K.2
Ohkita, T.3
-
82
-
-
0344837702
-
Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale
-
Terashima M, Irinoda T, Kawamura H, et al. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother Pharmacol 2003;51:240-6 (Pubitemid 36469954)
-
(2003)
Cancer Chemotherapy and Pharmacology
, vol.51
, Issue.3
, pp. 240-246
-
-
Terashima, M.1
Irinoda, T.2
Kawamura, H.3
Takagane, A.4
Abe, K.5
Oyama, K.6
Fujiwara, H.7
Saito, K.8
Gotoh, M.9
Shirasaka, T.10
-
83
-
-
3142624519
-
Alternate-day oral therapy with TS-1 for advanced gastric cancer
-
Arai W, Hosoya Y, Hyodo M, et al. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol 2004;9:143-8 (Pubitemid 38899745)
-
(2004)
International Journal of Clinical Oncology
, vol.9
, Issue.3
, pp. 143-148
-
-
Arai, W.1
Hosoya, Y.2
Hyodo, M.3
Yokoyama, T.4
Hirashima, Y.5
Yasuda, Y.6
Nagai, H.7
Shirasaka, T.8
-
84
-
-
57849165882
-
Comparison of alternate-day versus consecutive-day treatment with S-1: Assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo
-
Arai W, Hosoya Y, Haruta H, et al. Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol 2008;13:515-20
-
(2008)
Int J Clin Oncol
, vol.13
, pp. 515-520
-
-
Arai, W.1
Hosoya, Y.2
Haruta, H.3
-
85
-
-
77950961920
-
Alternate-day treatment with S-1 in patients with gastric cancer: A retrospective study of strategies for reducing toxicity
-
Sakuma K, Hosoya Y, Arai W, et al. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol 2010;15:166-71
-
Int J Clin Oncol
, vol.2010
, Issue.15
, pp. 166-171
-
-
Sakuma, K.1
Hosoya, Y.2
Arai, W.3
-
86
-
-
77954361284
-
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
-
Hirose T, Fujita K, Nishimura K, et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010;24:529-36
-
(2010)
Oncol Rep
, vol.24
, pp. 529-536
-
-
Hirose, T.1
Fujita, K.2
Nishimura, K.3
-
87
-
-
79951609864
-
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: Influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
-
Kim KP, Jang G, Hong YS, et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011;104:605-12
-
Br J Cancer
, vol.2011
, Issue.104
, pp. 605-612
-
-
Kim, K.P.1
Jang, G.2
Hong, Y.S.3
-
88
-
-
79251549824
-
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study
-
Tsunoda A, Nakao K, Watanabe M, et al. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011;22:355-61
-
(2011)
Ann Oncol
, vol.22
, pp. 355-361
-
-
Tsunoda, A.1
Nakao, K.2
Watanabe, M.3
-
89
-
-
33749350447
-
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
-
DOI 10.1158/1078-0432.CCR-06-0747
-
Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5 (Pubitemid 44497265)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.18
, pp. 5491-5495
-
-
Mattison, L.K.1
Fourie, J.2
Desmond, R.A.3
Modak, A.4
Saif, M.W.5
Diasio, R.B.6
-
90
-
-
78049435885
-
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
-
van Kuilenburg AB, Meijer J, Mul AN, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010;128:529-38
-
(2010)
Hum Genet
, vol.128
, pp. 529-538
-
-
Van Kuilenburg, A.B.1
Meijer, J.2
Mul, A.N.3
|